Profund Advisors LLC Bei Gene, Ltd. Transaction History

Profund Advisors LLC

  • $2.59 Billion
  • Q3 2024

A detailed history of Profund Advisors LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Profund Advisors LLC holds 4,416 shares of BGNE stock, worth $1 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
4,416
Previous 4,780 7.62%
Holding current value
$1 Million
Previous $681,000 45.52%
% of portfolio
0.04%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$143.93 - $224.51 $52,390 - $81,721
-364 Reduced 7.62%
4,416 $991,000
Q2 2024

Aug 13, 2024
SELL
$129.52 - $174.32 $152,963 - $205,871
-1,181 Reduced 19.81%
4,780 $681,000
Q1 2024

May 08, 2024
SELL
$141.8 - $181.47 $65,795 - $84,202
-464 Reduced 7.22%
5,961 $932,000
Q4 2023

Feb 14, 2024
BUY
$158.67 - $201.58 $201,193 - $255,603
1,268 Added 24.59%
6,425 $1.16 Million
Q3 2023

Nov 13, 2023
BUY
$179.87 - $225.13 $125,009 - $156,465
695 Added 15.58%
5,157 $927,000
Q2 2023

Aug 10, 2023
SELL
$178.3 - $266.78 $117,856 - $176,341
-661 Reduced 12.9%
4,462 $795,000
Q1 2023

May 11, 2023
SELL
$215.53 - $274.5 $35,346 - $45,018
-164 Reduced 3.1%
5,123 $1.1 Million
Q4 2022

Feb 02, 2023
SELL
$125.51 - $229.3 $538,939 - $984,614
-4,294 Reduced 44.82%
5,287 $1.16 Million
Q3 2022

Nov 04, 2022
BUY
$131.8 - $202.24 $68,404 - $104,962
519 Added 5.73%
9,581 $1.29 Million
Q2 2022

Aug 01, 2022
BUY
$121.11 - $216.05 $64,793 - $115,586
535 Added 6.27%
9,062 $1.47 Million
Q1 2022

May 10, 2022
BUY
$146.52 - $269.56 $490,695 - $902,756
3,349 Added 64.68%
8,527 $1.61 Million
Q4 2021

Feb 08, 2022
SELL
$248.56 - $389.34 $890,839 - $1.4 Million
-3,584 Reduced 40.9%
5,178 $1.4 Million
Q3 2021

Nov 12, 2021
BUY
$249.6 - $403.14 $10,233 - $16,528
41 Added 0.47%
8,762 $3.18 Million
Q2 2021

Aug 12, 2021
SELL
$292.75 - $367.01 $29,567 - $37,068
-101 Reduced 1.14%
8,721 $2.99 Million
Q1 2021

May 14, 2021
BUY
$260.64 - $382.12 $263,507 - $386,323
1,011 Added 12.94%
8,822 $3.07 Million
Q4 2020

Feb 09, 2021
BUY
$221.31 - $316.61 $591,782 - $846,615
2,674 Added 52.05%
7,811 $2.02 Million
Q3 2020

Nov 13, 2020
BUY
$189.18 - $286.44 $176,694 - $267,534
934 Added 22.22%
5,137 $1.47 Million
Q2 2020

Aug 03, 2020
SELL
$123.9 - $195.41 $40,267 - $63,508
-325 Reduced 7.18%
4,203 $792,000
Q1 2020

May 15, 2020
SELL
$121.84 - $173.19 $322,754 - $458,780
-2,649 Reduced 36.91%
4,528 $557,000
Q4 2019

Feb 18, 2020
BUY
$115.78 - $208.34 $160,007 - $287,925
1,382 Added 23.85%
7,177 $1.19 Million
Q3 2019

Nov 12, 2019
SELL
$120.61 - $148.29 $169,095 - $207,902
-1,402 Reduced 19.48%
5,795 $710,000
Q2 2019

Aug 13, 2019
SELL
$113.99 - $146.86 $275,171 - $354,520
-2,414 Reduced 25.12%
7,197 $892,000
Q1 2019

May 15, 2019
BUY
$122.82 - $151.83 $351,019 - $433,930
2,858 Added 42.32%
9,611 $1.27 Million
Q4 2018

Feb 14, 2019
SELL
$107.01 - $175.15 $394,759 - $646,128
-3,689 Reduced 35.33%
6,753 $947,000
Q3 2018

Nov 13, 2018
SELL
$152.62 - $189.66 $246,939 - $306,869
-1,618 Reduced 13.42%
10,442 $1.8 Million
Q2 2018

Aug 13, 2018
SELL
$152.5 - $216.77 $383,995 - $545,826
-2,518 Reduced 17.27%
12,060 $1.85 Million
Q1 2018

May 14, 2018
SELL
$97.41 - $177.22 $121,275 - $220,638
-1,245 Reduced 7.87%
14,578 $2.45 Million
Q4 2017

Feb 14, 2018
BUY
$79.6 - $114.73 $812,954 - $1.17 Million
10,213 Added 182.05%
15,823 $1.55 Million
Q3 2017

Nov 13, 2017
BUY
$66.19 - $103.46 $6,486 - $10,139
98 Added 1.78%
5,610 $580,000
Q2 2017

Aug 11, 2017
BUY
N/A
5,512
5,512 $248,000

Others Institutions Holding BGNE

# of Institutions
253
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $23.5B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email